Vitruvias Therapeutics Recalls Thyroid Tablets Over Super Potency Concerns
Vitruvias Therapeutics, Inc. has announced a voluntary recall of one lot of Thyroid Tablets, USP 30 mg, identified as Lot No. 504950. This decision, made on August 21, 2026, follows testing that revealed the potential for the product to be super potent. The recall is significant as the consumption of superpotent thyroid tablets can lead to hyperthyroidism, which may manifest through symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, and heart rhythm disturbances. Certain populations, particularly the elderly, pregnant women, and infants, are at heightened risk from these effects, especially with prolonged use. Excess thyroid hormone levels in older adults have been linked to adverse cardiac outcomes, while overtreatment in pregnant women can increase the likelihood of maternal and fetal complications, including premature delivery and low birth weight. Similarly, infants receiving excessive thyroid treatment may experience negative impacts on growth and development. To date, Vitruvias Therapeutics has not reported any adverse events associated with this recall. The recalled Thyroid, USP is a natural preparation derived from porcine thyroid glands, containing levothyroxine and liothyronine, and is used in the treatment of hypothyroidism. The affected lot was distributed nationwide from January 31, 2025, to September 30, 2025. Consumers are advised to identify the product using the NDC, product description, lot number, and expiration date. Vitruvias Therapeutics is actively notifying wholesalers to halt distribution and is arranging for the destruction of the recalled products. Patients currently using the recalled lot should consult their healthcare provider before discontinuing use or seeking a replacement prescription. For further inquiries, consumers can contact Vitruvias Therapeutics via email or phone during business hours. Additionally, any adverse reactions or quality issues related to this product can be reported to the FDA's MedWatch Adverse Event Reporting program.




